Dianon Announces Acquisition of UroCor
By Labmedica staff writers
Posted on 20 Nov 2001
In a move to expand its line of cancer diagnostics, Dianon Systems, Inc. (Stratford, CT, USA) has acquired UroCor, Inc. (Oklahoma City, USA) in a stock-for-stock transaction. Dianon provides a full line of anatomic and molecular pathology testing services. Posted on 20 Nov 2001
UroCor markets a wide range of products for detecting, diagnosing, and treating prostate cancer, bladder cancer, kidney stones, and other urologic disorders. The company provides diagnostic services to detect major urologic conditions, enhance the accuracy of prognosis, monitor therapy, and identify recurrence.
"This acquisition represents a significant step in our mission to become the leader in cancer diagnostics through expert pathology, clinical, and genomic services,” said Kevin C. Johnson, chairman, president, and CEO of Dianon Systems.
Related Links:
UroCor
Dianon
Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
High-Density Lipoprotein Containing Cholesterol Assay
HDL-c direct FS
